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Abstract
Unresolved issues remain surrounding the treatment of human brucellosis. The
present work aims to provide useful information to help clinicians make decisions
when treating brucellosis patients. Information based on scientific evidence from clin‐
ical trials published over the past 30 years has been compiled and presented in an up‐
dated form, covering both focal and non-focal, or uncomplicated, human brucellosis.
This chapter shows that, despite the studies published in recent years, areas such as
the role of monotherapy or treatment in cases of focal disease, have not been ade‐
quately addressed in clinical trials, and demonstrates the need for further research.
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1. Introduction
Infection caused by Brucella spp. affects humans and different animal species. The infection of
animals is particularly significant in rural areas of developing countries because in addition
to the implications for human health, there are also serious economic implications [1]. Human
brucellosis remains a major human health problem in countries of the Middle East, North
Africa, and the Balkan Peninsula [2, 3]. Many of these countries lack adequate health care
coverage that can ensure a correct management of all detected cases.
Furthermore, the treatment of human brucellosis continues to present complications such as
the need for parenteral administration of aminoglycosides, the risk of inducing rifampicin
resistance in countries where tuberculosis poses a problem, and treatment compliance in a
disease in which symptoms disappear a few days after initiating therapy. Additionally, patient
follow-up in underdeveloped rural areas is difficult and approximately 10% of patients relapse
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[4]. Moreover, there is insufficient scientific evidence on the management of special patient
groups such as pregnant women or patients with focal infection.
In order to properly understand the current state of knowledge on antimicrobial treatment for
human brucellosis, it is important to be familiar with the clinical trials conducted on the
treatment of this infection, including those dealing with special populations (children,
pregnant women) or with focal complications (spondylitis, endocarditis, or neurobrucellosis).
In the last four years, several systematic reviews [4-6] and some new clinical trials [7-9] have
been published. Most of these studies have focused on patients with uncomplicated human
brucellosis. The present work aims to provide useful information extracted from published
clinical trials on human brucellosis in the past 30 years, such as establishing the most effective
evidence-based treatment regimens and identifying those treatment issues that remain unclear
or insufficiently addressed. This is an important step toward achieving the goal of aiding
clinicians in decision-making processes when treating brucellosis patients.
2. Which treatment regimens were most widely tested in clinical trials?
A search for clinical trials in patients with acute brucellosis published in the last 30 years was
conducted in MEDLINE, using the terms "Brucella (or human brucellosis) and therapy (or
treatment) and clinical trial." A total of 33 comparative clinical trials were found. The search
was completed by the literature cited in these clinical studies.
Interest in this topic is also reflected by the fact that in the last 20 years, there have been at least
five systematic reviews on the treatment of uncomplicated human brucellosis [4-6, 10, 11].
These reviews help us to summarize the evidence available to date. Table 1 shows the
comparative clinical trials conducted on patients with uncomplicated brucellosis. [COMP:
insert Table 1]
Author [Ref] Year Country Therapeutic regimen and duration (days) Follow-up
duration
(months)
Type of
study
Ariza [12] 1985 Spain TETR ó DX (30) + STP (21) vs DX (30) + RF (30) 6-24 R
Ariza [34] 1985 Spain TETR (21) + STP (14) vs TMP/SMX (45) 6-36 R
Colmenero [13] 1989 Spain DX (30) + STP (21) vs DX (45) + RF (45) 6 R
Acocella [14] 1989 Multinational TETR (21) + STP (14) vs DX (45) + STP (14) vs
DX (45) + RF (45)
12 R
Lang [15] 1990 Israel CPX (42) vs DX (42) + RF (42) 12 R
Solera [16] 1991 Spain DX (45) + STP (14) vs DX (45) + RF (45) 12 R
Lang [31] 1992 Israel Ceftriaxone (≥14) vs DX (28) + STP (14) 6 R
Ariza [17] 1992 Spain DX (45) + STP (15) vs DX (45) + RF (45) 15.7 R, DB
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Author [Ref] Year Country Therapeutic regimen and duration (days) Follow-up
duration
(months)
Type of
study
Montejo [18] 1993 Spain DX (42) + STP (14) vs DX (42) + STP (21) vs DX
(28) + RF (28) vs DX (42) + RF (42) vs DX (42) vs
TMP/SMX (180)
12 R
Akova [19] 1993 Turkey DX (42) + RF (42) vs OFX (42) + RF (42) 14.6 R
Colmenero [20] 1994 Spain DX (42) + STP (21) vs DX (42) + RF (42) 6 R
Solera [21] 1995 Spain DX (45) + STP (14) vs DX (45) + RF (45) 12 R
Kalo [22] 1996 Albania DX (42) + RF (42) vs DX (42) + CPX (42) 6 R
Solera [42] 1997 Spain DX (30) + G (7) vs DX (45) + G (7) 12 NR
Agalar [23] 1999 Turkey DX (45) + RF (45) vs CPX (30) + RF (30) 12 R
Saltoglu [24] 2002 Turkey DX (45) + RF(45) vs OFX (45) + RF (45) 6 R
Karabay [25] 2004 Turkey DX (45) + RF (45) vs OFX (30) + RF (30) ~5 R
Hasanjani
Roushan [43]
2004 Iran TMP/SMX (60) + RF (60) vs DX (60) + TMP/SMX
(60)
12 R
Solera [44] 2004 Spain DX (30) + G (7) vs DX (45) + G (7) 8.7 R, DB
Ersoy [26] 2005 Turkey DX (42) + STP (21) vs DX (42) + RF (42) vs OFX
(42) + RF (42)
6-18 R
Hasanjani
Roushan [32]
2006 Iran DX (45) + STP (14) vs DX (45) + G (7) 12 R
Ranjbar [27] 2007 Iran DX (56-84) + RF (56-84) + AMK (7) vs DX (56) +
RF (56)
6 R
Alavi [28] 2007 Iran DX (56) + RF (56) vs DX (56) + TMP/SMX (56) 6 R
Keramat [29] 2009 Iran DX (56-84) + RF (56-84) vs DX (56-84) + CPX
(56-84) vs CPX (56-84) + RF (56-84)
6 R
Hasanjani
Roushan [33]
2010 Iran DX (45) + STP (14) vs DX (56) + G (5) 12 R
Mile [7] 2012 Macedonia DX (45) + RF (45) vs DX (45) + RF (45) + G (7-10) ≥6 NR
Hashemi [30] 2012 Iran OFX (42) + RF (42) vs DX (42) + STP (21) vs DX
(42) + RF (42)
6 R
Sofian [9] 2014 Iran DX (42) + RF (42) + STP (7) vs DX (56) +RF (56) +
STP (7)
24 R
Abbreviations: DX = doxycycline; RF = rifampicin; TETR = tetracycline; STP = streptomycin; TMP/SMX = cotrimoxazole;
CPX = ciprofloxacin; OFX = ofloxacin; G = gentamicin; AMK = amikacin; R = randomized; NR = non-randomized; DB =
double-blind.
Table 1. Comparative clinical trials in uncomplicated human brucellosis
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The therapeutic regimens most tested were those including two drugs. In uncomplicated
human brucellosis, the combination most often used in two-drug trials was that of doxycycline
and rifampicin, included in 20 clinical trials [7, 12-30], followed by the regimen including
doxycycline and streptomycin, in 13 clinical trials [12-14, 16-18, 20, 21, 26, 30-33]. In 12 of these
13 trials, the combination of doxycycline and streptomycin was compared to the combination
of doxycycline and rifampicin. In another nine clinical trials, an antimicrobial regimen
including quinolones was tested [15, 19, 22-26, 29, 30]. In one of them, quinolone was evaluated
as monotherapy [15] and in the other eight, quinolone in combination with another antimi‐
crobial agent, usually rifampicin. In all cases in which quinolones were used, they were
compared with doxycycline and rifampicin.
There were only three trials including triple-drug therapy [7, 9, 27], which in all cases consisted
of a combination of doxycycline, rifampicin, and an aminoglycoside. In two of these studies,
triple-drug therapy was compared with doxycycline and rifampicin. In the remaining study,
two different durations of the same triple-drug therapy were compared.
Four studies included trials with only a single antimicrobial agent. One trial was performed
using ceftriaxone [31] and another one using ciprofloxacin [15]. In another two, the antimi‐
crobial agent evaluated was cotrimoxazole [18, 34]. Only one clinical trial utilizing monother‐
apy with doxycycline has been conducted over the last 30 years [18]. The last study involving
monotherapy was published by Montejo et al. in 1993 [18]. Since then, there have been no
clinical trials conducted on human brucellosis assessing treatment with single antimicrobial
agents.
3. Which therapeutic regimens based on a combination of two
antimicrobial agents produced the highest cure rates?
The percentage of relapses and treatment failures obtained in clinical trials assessing the most
commonly used regimens, are shown in Table 2. The data in Table 2 support the conclusion
that the combination of doxycycline and streptomycin produces the highest cure rates and
therefore the lowest rates of treatment failures and relapses. [COMP: insert Table 2]
Reference N Relapses Therapeutic
failures
Comments
DOXYCYCLINE + STREPTOMYCIN
12 28 2 0 Some patients were treated with tetracycline. Treatment
duration was 30 days for doxycycline and 21 days for
streptomycin.
14 53 0 2
13 59 3 2 Treatment duration was 30 days for doxycycline and 21
days for streptomycin.
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Reference N Relapses Therapeutic
failures
Comments
16 38 2 1
31 10 0 0 Treatment duration was 28 days for doxycycline and 14
days for streptomycin..
17 51 3 2
18 84 4 0 40 patients with 14 days of streptomycin and another 44
patients with 21 days of streptomycin were included.
20 10 0 0
21 94 5 2
26 32 3 1 Treatment with streptomycin was maintained for 21 days.
32 94 3 4
33 82 5 4
30 65 3 3 Treatment with streptomycin was maintained for 21 days.
Total 839 37 (4.4%) 26 (3.1%)
DOXYCYCLINE + RIFAMPICIN
12 18 7 0 The treatment duration was 30 days.
13 52 7 0
14 63 3 0
15 4 0 0
16 38 9 3
17 44 6 2
18 111 19 2 65 of these patients received treatment for 4 weeks and the
remaining patients for 6 weeks.
19 30 1 0
20 10 1 1
21 100 16 8
22 12 1 0
23 20 2 0
24 30 2 NR
25 14 2 0
26 45 6 1
27 110 9 13 Treatment was maintained for 8 weeks.
28 51 6 5 Treatment was maintained for 8 weeks.
29 61 2 2
7 94 13 5
30 62 9 10
Total 969 121 (21.8%) 52 (5.4%)
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Reference N Relapses Therapeutic
failures
Comments
QUINOLONE + RIFAMPICIN ÓR DOXYCYCLINE
19 31 1 1 Quinolone + rifampicin
22 12 1 0 Quinolone + doxycycline
23 20 3 0 Quinolone + rifampicin. Treatment duration was 30 days.
24 27 2 NR Quinolone + rifampicin
25 15 2 0 Quinolone + rifampicin. Treatment duration was 30 days.
26 41 5 1 Quinolone + rifampicin
29 117 10 10 In 55 patients, ciprofloxacin plus doxycycline regimen was
used. In another 62 patients, ciprofloxacin plus rifampicin
regimen was used. The treatment duration ranged from 56
to 84 days.
30 64 5 4 Quinolone + rifampicin
Total 327 29 (8.9%) 16 (4.9%)
Table 2. Relapses and treatment failures in different therapeutic regimens used in clinical trials
4. Is triple-drug antimicrobial therapy better than the combination of two
antimicrobial agents for the treatment of uncomplicated brucellosis?
Only three clinical trials using a triple-drug antimicrobial therapy for the treatment of
uncomplicated human brucellosis have been published (Table 3). All these trials used a
combination of doxycycline, rifampicin, and an aminoglycoside during the initial days of
treatment. [COMP: insert Table 3]
The first of these trials was published by Ranjbar et al. in 2007 [27]. In this trial, a treatment
regimen with doxycycline and rifampicin was used for a period ranging from 8 to 12 weeks,
with amikacin for the first seven days. This regimen was compared to a combination of
doxycycline and rifampicin, also lasting for 8-12 weeks. The authors suggested that triple-drug
therapy was beneficial with respect to the dual-drug therapy, based on greater efficiency in
terms of relief of symptoms, with borderline significance (p = 0.04; 95% Confidence Interval =
0.008 to 0.15). In terms of relapse, no significant differences between the two treatment groups
(p = 0.4) were obtained.
The second trial was conducted by Mile et al. [7]. It was a non-randomized study comparing
the efficacy and tolerance of a doxycycline-rifampicin regimen administered for 45 days (94
patients), versus doxycycline-rifampicin regimen given for 45 days plus gentamicin for the
first 7-10 days (87 patients). The doxycycline-rifampicin-gentamicin regimen demonstrated a
significantly lower relapse rate in comparison to the doxycycline-rifampicin combination (p =
0.034). Interestingly, in this second study, treatment failure rates were similar in both groups
and no significant differences were found in overall cure rate (p = 0.097).
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Reference N Relapses Treatment failures Comments
DOXYCYCLINE + RIFAMPICIN + AMINOGLYCOSIDE
27 110 6 4 The duration of treatment ranged from 8 to 12 weeks. The
aminoglycoside amikacin was used for 7 days.
7 87 4 5 The treatment duration was 45 days. The aminoglycoside
gentamicin was used for the first 7-10 days.
9 72 10 0 The treatment duration was 6 weeks. The aminoglycoside
streptomycin was used for the first 7 days.
9 72 7 0 The treatment duration was 8 weeks. The aminoglycoside
streptomycin was used for the first 7 days.
Total 341 27 (7.9%) 9 (2.6%)
Table 3. Relapses and treatment failures with triple-drug therapy in clinical trials on human brucellosis
The third study was published in 2014 by Sofian et al. [9]. It was a randomized, controlled trial
to compare the triple-drug regimen of doxycycline and rifampicin for six weeks plus strepto‐
mycin for the first seven days, versus doxycycline and rifampicin for eight weeks plus
streptomycin for seven days. This trial found no significant difference between six weeks and
eight weeks of treatment (p = 0.42).
On the basis of these trials, it cannot be concluded that treatment with three drugs is currently
a better therapeutic regimen than treatment with two drugs. There are several arguments to
support this conclusion. Firstly, only two of these trials compared triple-drug therapy with
dual-drug therapy, and the results between these two trials were contradictory. Whereas in
the first trial, triple-drug therapy was better in terms of relief of symptoms but not in terms of
relapse rates, in the second trial, the contrary occurs, with triple-drug therapy more effective
in preventing relapses but not in short-term treatment success. Moreover, failure and relapse
rates obtained in these trials with triple-drug therapy were no lower than those obtained in
other dual-drug therapy trials using doxycycline and streptomycin (Tables 2 and 3). Further‐
more, triple-drug therapy renders treatment more complicated, with increased costs. In
addition, the effects resulting from the difficulty of administering this treatment in developing
countries should also be considered [4]. Therefore, until more data are available, we cannot
conclude that triple-drug therapy is better than two-drug treatment.
5. Is monotherapy a valid alternative?
Human brucellosis is a disease with low mortality rates and good response to different
therapeutic regimens. Most cases occur in developing countries with limited resources. This
fact has led some authors to consider the use of more simple and inexpensive therapeutic
regimens based on monotherapy.
Only four of the studies included in Table 1 tested therapeutic regimens based on monotherapy
in uncomplicated adult human brucellosis. Monotherapy with cotrimoxazole for 45 days was
evaluated by Ariza et al., and they obtained a high relapse rate (46.6%) [34]. Montejo et al. were
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able to reduce the recurrence rate with cotrimoxazole to 3.1%, but at the cost of prolonging the
treatment for 6 months [18], which also increases the probability of side effects or of the
patient’s abandonment of treatment.
Lang et al. performed two monotherapy trials with a small number of patients. In the first of
these trials, six patients treated with a six-week regimen of oral ciprofloxacin were included
[15]. Of these patients, five relapsed. In the second clinical trial, eight patients were treated
with intramuscular ceftriaxone for at least two weeks [31]. Only two patients in this group
responded to treatment.
However, unlike in the previously described trials, in the study conducted by Montejo et al.
[18], the results obtained with doxycycline monotherapy were better, showing a relapse rate
of 14.1%, which was only slightly higher than that obtained in the same study with the
combination of doxycycline and rifampicin for 45 days (11%). These results were also better
than those obtained with rifampicin and doxycycline for 30 days (21.5% relapse rate). Doxy‐
cycline monotherapy appears to yield similar outcomes to those obtained by some of the trials
using both doxycycline and rifampicin that are reflected in Table 2.
Therefore, it has been postulated that monotherapy with doxycycline can be a cost-effective
treatment in patients without focal disease and with low risk of relapse. Solera et al. [35]
identified as predictors of relapse a baseline temperature more than 38.3°C, duration of
symptoms to be less than 10 days before starting the treatment, and baseline positive blood
cultures. In patients with none or one of these factors, the risk of recurrence is low, and
doxycycline monotherapy might be an appropriate treatment. Further clinical trials are needed
to confirm this hypothesis.
6. Which treatment regimens were used in clinical trials on brucellosis in
children?
There were three trials conducted in children with brucellosis. Firstly, the trial by Lubani et al.
[36] was performed using a variety of therapeutic regimens. Excluding cotrimoxazole mono‐
therapy, which showed a high rate of relapse (30%), the rest of the treatment regimens in the
study (including monotherapy regimens) demonstrated good results with low relapse and
treatment failure rates. The authors of this trial recommend cotrimoxazole and gentamicin-
containing regimens for patients aged 8 years or younger, for whom tetracyclines are contra‐
indicated.
Khuri-Bulos et al. [37] conducted a study in which 113 children were treated with a six-week
combination of trimethoprim-sulfamethoxazole (10 to 12 mg/kg trimethoprim, 50 to 60 mg/kg
sulfamethoxazole) and rifampicin (15 to 20 mg/kg in two divided doses). The treatment was
well-tolerated, and only four children relapsed during the six-month follow-up.
Hasanjani Roushan et al. [38] published a study on two different durations for a regimen
including cotrimoxazole and rifampicin (42 versus 56 days of treatment). After a year of follow-
up, the authors observed a similar cure rate in the two treatment groups (89.1% and 95.5% cure
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rate for 42 and 56 days, respectively; p = 0.204). The authors reached the conclusion that a six-
week treatment duration was sufficient to treat brucellosis.
Considering these data, it can be stated that childhood brucellosis responds to treatment
regimens that include cotrimoxazole, gentamicin, and rifampicin, with a low failure rate and
relapse. Although recommended regimens are those including cotrimoxazole or rifampicin
for 45 days plus gentamicin in the first seven days [1], clinical trials also showed a good
treatment response rate to cotrimoxazole plus rifampicin for six weeks.
7. Which treatment regimens were used in clinical trials for the treatment
of brucella spondylitis?
There were two clinical trials on patients with brucellar spondylitis. The first was performed
by Bayindir et al. [39]. In this study, 102 patients suffering from a lumbar brucellar spondylitis
were randomized to receive five different regimens of antibiotic therapy: streptomycin (15
days) plus tetracycline (45 days), doxycycline (45 days) plus streptomycin (15 days), doxycy‐
cline plus rifampicin (45 days), ofloxacin plus rifampicin (45 days), and finally doxycycline
plus rifampicin (45 days) plus streptomycin (15 days). The only group in which there were no
relapses or treatment failures was the one that received triple-drug therapy with doxycycline,
rifampicin, and streptomycin. Thus, this treatment was recommended by the study authors
according to their results.
The other trial, conducted by Alp et al. [40], included 31 patients with spinal brucellosis who
were consecutively assigned to one of two treatment regimens tested. These treatments were
either a combination of doxycycline and streptomycin, or a combination of ciprofloxacin with
rifampicin. Treatment was continued for an average of 12 weeks. The authors concluded that
the success rate with each combination was the same, but based on the lower cost of treatment,
the authors recommended the combination of streptomycin and doxycycline.
According to these two trials, it may be concluded that triple-drug therapy successfully treats
brucellar spondylitis with a short course of just 45 days of antibiotics versus dual-drug therapy.
However, despite the greater methodological difficulties of the second trial described here,
therapy with doxycycline and streptomycin could be an alternative if treatment time is
prolonged.
8. Which treatment regimens were used in clinical trials on brucellosis in
pregnancy?
No clinical trials on the treatment of brucellosis during pregnancy were found. Therefore, the
therapy in this group of patients is mainly based on expert recommendations and observatio‐
nal studies. Tetracycline and streptomycin should be avoided during pregnancy. The regimen
of choice includes rifampicin 900 mg daily for six weeks. Trimethoprim-sulfamethoxazole
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could be combined with rifampicin, but should not be used before 13 weeks of pregnancy
because of teratogenic risk nor after 36 weeks due to risk of kernicterus [1, 3].
9. Which treatment regimens were used in clinical trials for the treatment
of Brucella endocarditis?
Likewise, no clinical studies were found on patients suffering from Brucella endocarditis and,
as with brucellosis during pregnancy, the therapy in this group of patients is mainly based on
expert recommendations and observational studies. Antibiotics used in these cases include
doxycycline, rifampicin, and aminoglycosides in triple-drug therapy and sometimes cotri‐
moxazole [1, 3]. Brucella endocarditis requires prolonged treatment for 2 to 10 months and
must be maintained on the basis of clinical, laboratory, and echocardiographic data. In cases
of persistent infection, prosthetic valve infection, heart failure, abscesses or periannular
extension of infection, surgery is indicated [3].
10. Which treatment regimens were used in clinical trials for the treatment
of neurobrucellosis?
Involvement of the nervous system in Brucella infection may have different manifestations
such as meningoencephalitis, myelitis, radiculitis, peripheral neuropathies, subarachnoid
hemorrhage, or psychiatric manifestations [41]. There is no consensus on antibiotic therapy
for neurobrucellosis. No clinical trials on patients suffering from neurobrucellosis have been
found. Dual- or triple-combination therapy with doxycycline, rifampicin, trimethoprim-
sulfamethoxazole, and aminoglycosides has been recommended [3, 41]. Neurobrucellosis may
require prolonged courses of treatment over several months.
11. What systematic reviews have been conducted on the treatment of
human brucellosis?
Until now, five systematic reviews on the treatment of human brucellosis have been conducted
[4-6, 10, 11] (Table 4). The first was published in 1997 and was performed with the aim of
comparing a doxycycline plus streptomycin regimen with a doxycycline plus rifampicin
regimen [10]. The authors concluded that the doxycycline-rifampicin treatment presented a
greater number of relapses and a lower number of cures than streptomycin-doxycycline
treatment.
The next published systematic review was performed by Skalski et al. [11], which recom‐
mended triple-drug therapy as one of the most appropriate regimens. However, as indicated
by Yousefi-Nooraie et al. [5], the review had some methodological limitations, such as
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combining trials based on different drug classes (e.g., comparing quinolone with non-
quinolone-based regimens) or comparing studies on brucellar spondylitis with studies on non-
complicated brucellosis, despite differences in the treatment duration of these studies.
Since then, three other systematic reviews have been published [4-6]. Despite some differences
in the methodology used among the three, the conclusion they all reached was that the
combination of doxycycline-aminoglycoside [especially doxycycline (six weeks) plus strepto‐
mycin (two or three weeks)] in uncomplicated adult brucellosis was more effective than a
doxycycline plus rifampicin (six-week) regimen.
Author [Ref] Year Conclusions
Solera [10] 1994 “In human brucellosis, treatment with rifampicin and doxycycline
presents a greater number of recurrences and a lower number of cures
than the classical treatment with streptomycin and tetracycline drugs.”
Skalsky [11] 2008 “There are significant differences in effectiveness between currently
recommended treatment regimens for brucellosis. The preferred
treatment should be with dual or triple regimens including an
aminoglycoside.”
Solís García del Pozo [4] 2012 “Although the preferred treatment in uncomplicated human brucellosis
is a doxycycline-aminoglycoside combination, other treatments based on
oral regimens or monotherapy should not be rejected until they are
better studied. Triple therapy should not be considered the current
treatment of choice.”
Yousefi-Nooraie [5] 2012 “A doxycycline (six weeks) plus streptomycin (two or three weeks)
regimen is more effective than a doxycycline plus rifampicin (six weeks)
regimen. Quinolone plus rifampicin (six weeks) is slightly better
tolerated than doxycycline plus rifampicin, and low quality evidence did
not show any difference in overall effectiveness.”
Alavi [6] 2013 “In uncomplicated brucellosis in adult patients, a doxycycline-
aminoglycoside combination is the first choice, with doxycycline-
rifampin and doxycycline-cotrimoxazole as alternative regimens. The
other oral regimens including quinolones may be considered as
alternatives. Cotrimoxazole plus rifampin for six weeks may be the
regimen of choice for the treatment of patients younger than 8 years old.
Gentamicin for 5 days plus cotrimoxazole for six weeks may be a
suitable alternative regimen.”
Table 4. Main conclusions of the systematic reviews published on treatment of human brucellosis
12. Conclusions
Over the past few years, several trials and systematic reviews on the treatment of human
brucellosis have been published. However, unresolved issues remain surrounding the
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treatment of this disease that may be important for patient management, such as the role of
monotherapy in low risk patients, or treatment for special groups such as those with focal
disease. These unresolved issues have not been adequately addressed in clinical trials. Further
research on the treatment of this zoonosis is necessary to provide the clinician with the best
scientific evidence upon which to base clinical decisions.
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